IL237072B - History of isoquinolinone, their preparation and pharmaceutical preparations containing them - Google Patents

History of isoquinolinone, their preparation and pharmaceutical preparations containing them

Info

Publication number
IL237072B
IL237072B IL237072A IL23707215A IL237072B IL 237072 B IL237072 B IL 237072B IL 237072 A IL237072 A IL 237072A IL 23707215 A IL23707215 A IL 23707215A IL 237072 B IL237072 B IL 237072B
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
isoquinolinone derivatives
isoquinolinone
Prior art date
Application number
IL237072A
Other languages
English (en)
Hebrew (he)
Inventor
Buchstaller Hans-Peter
Dorsch Dieter
Original Assignee
Hans Peter Buchstaller
Dorsch Dieter
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Peter Buchstaller, Dorsch Dieter, Merck Patent Gmbh filed Critical Hans Peter Buchstaller
Publication of IL237072B publication Critical patent/IL237072B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL237072A 2012-08-08 2015-02-03 History of isoquinolinone, their preparation and pharmaceutical preparations containing them IL237072B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12005752 2012-08-08
PCT/EP2013/002085 WO2014023390A2 (en) 2012-08-08 2013-07-12 (aza-)isoquinolinone derivatives

Publications (1)

Publication Number Publication Date
IL237072B true IL237072B (en) 2018-11-29

Family

ID=48793165

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237072A IL237072B (en) 2012-08-08 2015-02-03 History of isoquinolinone, their preparation and pharmaceutical preparations containing them

Country Status (23)

Country Link
US (1) US9376433B2 (enExample)
EP (1) EP2882714B1 (enExample)
JP (2) JP6247294B2 (enExample)
KR (1) KR102083154B1 (enExample)
CN (1) CN104507912B (enExample)
AR (1) AR092366A1 (enExample)
AU (1) AU2013301870B2 (enExample)
BR (1) BR112015002601A2 (enExample)
CA (1) CA2881330C (enExample)
DK (1) DK2882714T3 (enExample)
ES (1) ES2773272T3 (enExample)
HR (1) HRP20200180T1 (enExample)
HU (1) HUE047608T2 (enExample)
IL (1) IL237072B (enExample)
LT (1) LT2882714T (enExample)
MX (1) MX362939B (enExample)
PL (1) PL2882714T3 (enExample)
PT (1) PT2882714T (enExample)
RS (1) RS59921B1 (enExample)
RU (1) RU2654216C2 (enExample)
SG (1) SG11201500732TA (enExample)
SI (1) SI2882714T1 (enExample)
WO (1) WO2014023390A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2942847B2 (ja) 1990-06-22 1999-08-30 ダイセル化学工業株式会社 液晶性ポリマーフィルムの製造装置とそれを用いた液晶性ポリマーフィルムの製造方法
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
CA2922469A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
JP6359175B2 (ja) * 2014-04-10 2018-07-18 フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド PARP阻害剤としての4H‐ピラゾロ[1,5‐α]ベンゾイミダゾール化合物のアナログ
CN105153156B (zh) * 2015-09-22 2017-07-28 徐峰 一种4‑苯基‑2,7‑萘啶‑1(2h)‑酮的制备方法
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2017160898A1 (en) * 2016-03-15 2017-09-21 Purdue Research Foundation Aza-a-ring indenoisoquinoline topoisomerase i poisons
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
EP3558993A4 (en) 2016-12-22 2020-05-06 Purdue Research Foundation AZAINDENOISOCHINOLINE COMPOUNDS AND USES THEREOF
US10899733B2 (en) 2017-08-23 2021-01-26 Oregon Health & Science University Inhibitors of PARPs that catalyze mono-ADP-ribosylation
RU2709928C1 (ru) * 2019-02-21 2019-12-24 Федеральное государственное бюджетное научное учреждение "Институт природно-технических систем" (ИПТС) Датчик удельной электропроводности
JPWO2024029583A1 (enExample) * 2022-08-05 2024-02-08
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU9298098A (en) * 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
WO1999018077A1 (en) * 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
EA200100124A1 (ru) * 1998-08-11 2001-10-22 Пфайзер Продактс Инк. Замещенные 1,8-нафтиридин-4(1h)-оны в качестве ингибиторов фосфодиэстеразы 4
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2005075432A1 (ja) * 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha 1−(2h)−イソキノロン誘導体およびその抗ガン剤としての使用
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parpおよびtank阻害剤としてのキノリノン誘導体
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物
FR2956816B1 (fr) 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
US20130311482A1 (en) 2012-05-17 2013-11-21 Tagged, Inc. Multi-user timeline for facilitating social discovery in social networking environments

Also Published As

Publication number Publication date
KR20150041649A (ko) 2015-04-16
MX362939B (es) 2019-02-27
BR112015002601A2 (pt) 2017-07-04
WO2014023390A2 (en) 2014-02-13
US9376433B2 (en) 2016-06-28
DK2882714T3 (da) 2020-01-20
CN104507912B (zh) 2016-09-28
ES2773272T3 (es) 2020-07-10
JP6333450B2 (ja) 2018-05-30
PT2882714T (pt) 2020-02-19
KR102083154B1 (ko) 2020-03-02
JP2015524450A (ja) 2015-08-24
RU2015107702A (ru) 2016-09-27
SI2882714T1 (sl) 2020-03-31
EP2882714A2 (en) 2015-06-17
AR092366A1 (es) 2015-04-15
US20150210686A1 (en) 2015-07-30
AU2013301870B2 (en) 2017-04-27
HUE047608T2 (hu) 2020-05-28
CA2881330A1 (en) 2014-02-13
LT2882714T (lt) 2020-03-10
MX2015001545A (es) 2015-05-11
RU2654216C2 (ru) 2018-05-17
RS59921B1 (sr) 2020-03-31
EP2882714B1 (en) 2019-11-13
HK1209106A1 (en) 2016-03-24
CN104507912A (zh) 2015-04-08
HRP20200180T1 (hr) 2020-05-01
SG11201500732TA (en) 2015-02-27
WO2014023390A3 (en) 2014-04-10
PL2882714T3 (pl) 2020-02-28
JP2018008974A (ja) 2018-01-18
CA2881330C (en) 2020-07-21
AU2013301870A1 (en) 2015-03-19
JP6247294B2 (ja) 2017-12-13

Similar Documents

Publication Publication Date Title
IL285390A (en) Arylquinazolines, their preparation and pharmaceutical preparations containing them
IL237839A0 (en) History of hydropyrrolopyrrole, their preparation and pharmaceutical preparations containing them
IL237073A (en) History of pyridopyrimidine, their preparation and their pharmaceutical preparations
IL235414A (en) The history of pyrolotriazinone, their preparation and their pharmaceutical preparations
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL236542A0 (en) History of pyrimidine pyrazolyl, their preparation and pharmaceutical preparations containing them
IL240876B (en) History of aminopurine, their preparation and pharmaceutical preparations containing them
IL252566A0 (en) Pharmacy preparations and methods
IL238060B (en) 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
IL238825A0 (en) The history of heterocyclics, their preparation and pharmaceutical preparations containing them
IL232577A0 (en) The history of morpholinylbenzotriazine, their preparation and pharmaceutical preparations containing them
IL233602A (en) The history of benzamide, their preparation and their pharmaceutical preparations
IL239054A0 (en) History of azaquinazoline carboxamide, their preparation and pharmaceutical preparations containing them
IL243982A0 (en) History of piperidine urea, their preparation and pharmaceutical preparations containing them
IL235955A0 (en) The history of benzothiophene, their preparation and pharmaceutical preparations containing them
IL237146A0 (en) Pharmaceutical compound containing Rabamipide
IL230219A0 (en) History of dihydropyrazole, their preparation and pharmaceutical preparations containing them
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
IL246298B (en) History of piperidine, their preparation and pharmaceutical preparations containing them
IL243227B (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
IL243223B (en) History of imidazole, their preparation and pharmaceutical preparations containing them
IL235947A (en) Solid state isonicotinamide history and their medicinal preparations
IL238826A0 (en) History of imidazole - piperidinyl, their preparation and pharmaceutical preparations containing them
IL239873B (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed